Since B-ALL cells predominantly localize in the BM mimicking the minimal residual disease, the authors treated mice with a single intra-femoral injection of CD19 CAR-NK cells at 100 days post-tumor challenge and observed a potent anti-tumor response, with undetectable level of leukemia cells in the femur. This evidence concerns the gene CD19 and leukemia.